Bivalirudin versus heparin and provisional GP IIb/IIIa inhibitors in patients treated for ST-segment elevation myocardial infarctions: Comparison of outcomes in a "real-world" setting.
Andreas FachTina BackhausJohannes SchmuckerRobert ZabrockiDaniela GarstkaJanina StehmeierEduard FiehnRainer HambrechtHarm WienbergenPublished in: Journal of interventional cardiology (2017)
In this "real-world" cohort of patients with STEMI bivalirudin compared to heparin and GPIs was associated with less bleedings and no significant differences in stent thromboses, reinfarctions, and mortality during hospital and long-term course.
Keyphrases
- percutaneous coronary intervention
- venous thromboembolism
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- growth factor
- acute coronary syndrome
- coronary artery disease
- cardiovascular events
- healthcare
- left ventricular
- heart failure
- emergency department
- adverse drug
- cardiovascular disease
- type diabetes
- skeletal muscle
- electronic health record